1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
60F86EC48BFFA11E76525793B001C3ADF
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/oncology-market-education-communicating-with-the-medical-community?opendocument
18
19opendocument
203.88.156.58
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Market Entry and Oncology

Oncology Market Education: Communicating with the Medical Community

ID: 5165


Features:

6 Info Graphics

15 Data Graphics

144 Metrics

11 Narratives

3 Best Practices


Pages/Slides: 30


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Oncology Market Education: Communicating with the Medical Community"

STUDY OVERVIEW

The success of an oncology product launch hinges on many things but one of the critical components is the reception in the medical community. Thus market education efforts directed at the medical community are a part of every biopharma organization's launch plan, especially those in the oncology sector.

Best Practices, LLC conducted this study to explore the best practices in informing and preparing the medical community for new oncology products. In particular, it examines the use of data disclosures and scientific publications. In addition, the study looks at the balanced use of multi-channel education efforts to ensure the medical community understands the value of a new oncology product and its place among the many cancer weapons physicians can utilize.

KEY TOPICS

  • Use data disclosures to inform the medical community of both progress and commitment
  • Communicate clinical science through journals and congresses to position company as a thought leader
  • Utilize scientific publications to link together productivity and insights
  • Use multi-channel medical education to inform health care providers
  • Balance the mix of CME, grants and tools to best utilize medical education.

SAMPLE KEY METRICS
  • Data types employed on first release to inform the marketplace and comply with regulatory requirements for data integrity
  • Importance of publishing clinical results in various channels
  • Publishing mix in each of three tiers of publications during phase III to launch period
  • Number of publications expected to issue during the phase III to launch period to adequately prepare market for product entry
  • Top five most important activities in educating physicians
  • Start period of different activities for educating


SAMPLE KEY FINDINGS
  • Using Public Relations and Technology: New technologies and Public Relations are both “leveraged,” cost-efficient tools for education; both permit less control than companies customarily want. The development and pre-launch cycle offer many opportunities to use new technologies (e.g., social media, Internet, You Tube/video communication channels) to educate physicians, patients, payers and government.


METHODOLOGY
The benchmark class includes 34 executives and managers at 26 leading pharmaceutical, biotech and medical device companies. In addition, deep-dive executive interviews were conducted with selected participants to provide qualitative insights and emerging trends.

Industries Profiled:
Pharmaceutical; Biotech; Health Care; Service; Medical Device; Technology; Manufacturing; Consumer Products; Diagnostic; Chemical


Companies Profiled:
GlaxoSmithKline; ARIAD; Pfizer; Integrated Communications Corp.; Novartis; Genitope Corporation; NeoVista; Inc.; Amgen; Novo Nordisk; Johnson & Johnson; AstraZeneca; Roche; Lilly; Bayer; Human Genome Sciences; Boehringer Ingelheim; Nobel Biocare; Abbott; Solvay Pharmaceuticals; Genentech; Sanofi-aventis; Smith & Nephew; Amylin; Janssen Cilag Pharmaceutical; Dr Reddy's Laboratories; Spectrum Pharmaceutical


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.